The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma
Open accessAbstract
Angiogenesis is not only dependent on endothelial cell invasion and proliferation, it also requires pericyte coverage of vascular sprouts for stabilization of vascular walls. Clinical efficacy of angiogenesis inhibitors targeting the vascular endothelial growth factor (VEGF) signaling pathway is still limited to date. We hypothesized that the level of vessel maturation is critically involved in the response to antiangiogenic therapies. To test this hypothesis, we evaluated the vascular network in spontaneously developing melanomas of MT/ret transgenic mice after using PTK787/ZK222584 for anti-VEGF therapy but also analyzed human melanoma metastases taken at clinical relapse in patients undergoing adjuvant treatment using bevacizumab. Both experimental settings showed that tumor vessels, which are resistant to anti-VEGF therapy, are characterized by enhanced vessel diameter and normalization of the vascular bed by coverage of mature pericytes and immunoreactivity for desmin, NG-2, platelet-derived growth factor receptor β, and the late-stage maturity marker α smooth muscle actin. Our findings emphasize that the level of mural cell differentiation and stabilization of the vascular wall significantly contribute to the response toward antiangiogenic therapy in melanoma. This study may be useful in paving the way toward a more rational development of second generation antiangiogenic combination therapies and in providing, for the first time, a murine model to study this.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“This results in vessel stabilization and reduced vascular permeability, which facilitates access of coadministered chemotherapeutic drugs (Jain 2005).”
Angiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Endothelial/Pericyte Interactions
Armulik, A., Abramsson, A., & Betsholtz, C. (2005) · Circulation Research · doi:10.1161/01.res.0000182903.16652.d7 · Cited by 2,048
Bingle, L., Brown, N. J., & Lewis, C. E. (2002) · The Journal of Pathology · doi:10.1002/path.1027 · Cited by 2,022
Induction of angiogenesis during the transition from hyperplasia to neoplasia
Folkman, J., Watson, K., Ingber, D., & Hanahan, D. (1989) · Nature · doi:10.1038/339058a0 · Cited by 1,879
Angiopoietins: a link between angiogenesis and inflammation
Fiedler, U., & Augustin, H. G. (2006) · Trends in Immunology · doi:10.1016/j.it.2006.10.004 · Cited by 606
Self-citation
Research works printed but not linked: 49
- Abramsson, 2003, Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors, J. Clin. Invest., 112, 1142, 10.1172/JCI200318549 · DOI
- Andrae, 2008, Role of platelet-derived growth factors in physiology and medicine, Genes Dev., 22, 1276, 10.1101/gad.1653708 · DOI · Paper page
- Benjamin, 1998, A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF, Development., 125, 1591, 10.1242/dev.125.9.1591 · DOI · Paper page
- Bergers, 2003, Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors, J. Clin. Invest., 111, 1287, 10.1172/JCI200317929 · DOI
- Betsholtz, 2005, Role of pericytes in vascular morphogenesis, EXS., 94, 115
- Carlson, 2001, Direct cell adhesion to the angiopoietins mediated by integrins, J. Biol. Chem., 276, 26516, 10.1074/jbc.M100282200 · DOI · Paper page
- Carmeliet, 2005, Angiogenesis in life, disease and medicine, Nature., 438, 932, 10.1038/nature04478 · DOI · Paper page
- de Visser, 2006, The inflammatory tumor microenvironment and its impact on cancer development, Contrib. Microbiol., 13, 118, 10.1159/000092969 · DOI · Paper page
- Döme, 2002, Vascularization of cutaneous melanoma involves vessel co-option and has clinical significance, J. Pathol., 197, 355, 10.1002/path.1124 · DOI
- Erber, 2004, Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms, FASEB J., 18, 338, 10.1096/fj.03-0271fje · DOI · Paper page
- Escudier, 2007, Sorafenib in advanced clear-cell renal-cell carcinoma, N. Engl. J. Med., 356, 125, 10.1056/NEJMoa060655 · DOI · Paper page
- Fallowfield, 1991, The vascularity of primary cutaneous melanoma, J. Pathol., 164, 241, 10.1002/path.1711640309 · doi:10.1002/path.1711640309
- Fiedler, 2004, The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies, Blood., 103, 4150, 10.1182/blood-2003-10-3685 · DOI · Paper page
- Gerhardt, 2003, Endothelial-pericyte interactions in angiogenesis, Cell Tissue Res., 314, 15, 10.1007/s00441-003-0745-x · DOI · Paper page
- Gupta, 2006, Ultra-high resolution flat-panel volume CT: fundamental principles, design architecture, and system characterization, Eur. Radiol., 16, 1191, 10.1007/s00330-006-0156-y · DOI · Paper page
- Hagemann, 2009, Regulation of macrophage function in tumors: the multifaceted role of NF-kappaB, Blood., 113, 3139, 10.1182/blood-2008-12-172825 · DOI · Paper page
- Hanahan, 1997, Signaling vascular morphogenesis and maintenance, Science., 277, 48, 10.1126/science.277.5322.48 · DOI · Paper page
- Hanahan, 1996, Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis, Cell., 86, 353, 10.1016/S0092-8674(00)80108-7 · DOI · Paper page
- Helfrich, 2009, Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma, Clin. Cancer Res., 15, 1384, 10.1158/1078-0432.CCR-08-1615 · DOI · Paper page
- Hellström, 1999, Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse, Development., 126, 3047, 10.1242/dev.126.14.3047 · DOI · Paper page
- Hess-Stumpp, 2005, PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy, ChemBioChem., 6, 550, 10.1002/cbic.200400305 · DOI
- Holash, 1999, Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF, Science., 284, 1994, 10.1126/science.284.5422.1994 · DOI · Paper page
- Ilmonen, 1999, Prognostic value of tumour vascularity in primary melanoma, Melanoma Res., 9, 273, 10.1097/00008390-199906000-00009 · DOI
- Kato, 1998, Transgenic mouse model for skin malignant melanoma, Oncogene., 17, 1885, 10.1038/sj.onc.1202077 · DOI · Paper page
- Kiessling, 2004, Volumetric computed tomography (VCT): a new technology for noninvasive, high-resolution monitoring of tumor angiogenesis, Nat. Med., 10, 1133, 10.1038/nm1101 · DOI · Paper page
- Kunkel, 2001, Expression and localization of scatter factor/hepatocyte growth factor in human astrocytomas, Neuro-oncol., 3, 82, 10.1215/15228517-3-2-82 · doi:10.1215/15228517-3-2-82
- Küsters, 2002, Vascular endothelial growth factor-A(165) induces progression of melanoma brain metastases without induction of sprouting angiogenesis, Cancer Res., 62, 341
- Leenders, 2002, Design of a variant of vascular endothelial growth factor-A (VEGF-A) antagonizing KDR/Flk-1 and Flt-1, Lab. Invest., 82, 473, 10.1038/labinvest.3780440 · DOI
- Leenders, 2002, Vessel co-option: how tumors obtain blood supply in the absence of sprouting angiogenesis, Endothelium., 9, 83, 10.1080/10623320212006 · DOI
- Maisonpierre, 1997, Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis, Science., 277, 55, 10.1126/science.277.5322.55 · DOI · Paper page
- Morikawa, 2002, Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors, Am. J. Pathol., 160, 985, 10.1016/S0002-9440(10)64920-6 · DOI · Paper page
- Nasarre, 2009, Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth, Cancer Res., 69, 1324, 10.1158/0008-5472.CAN-08-3030 · DOI · Paper page
- Nehls, 1992, Pericyte involvement in capillary sprouting during angiogenesis in situ, Cell Tissue Res., 270, 469, 10.1007/BF00645048 · DOI · Paper page
- Neufeld, 1999, Vascular endothelial growth factor (VEGF) and its receptors, FASEB J., 13, 9, 10.1096/fasebj.13.1.9 · DOI · Paper page
- Paku, 1998, Current concepts of tumor-induced angiogenesis, Pathol. Oncol. Res., 4, 62, 10.1007/BF02904699 · DOI
- Perez, 2009, Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A, Cancer., 115, 119, 10.1002/cncr.23987 · DOI
- Pezzella, 1997, Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis, Am. J. Pathol., 151, 1417
- Pichiule, 2004, Hypoxic regulation of angiopoietin-2 expression in endothelial cells, J. Biol. Chem., 279, 12171, 10.1074/jbc.M305146200 · DOI · Paper page
- Scharpfenecker, 2005, The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism, J. Cell Sci., 118, 771, 10.1242/jcs.01653 · DOI · Paper page
- Shieh, 2009, Tumor-associated macrophage correlated with angiogenesis and progression of mucoepidermoid carcinoma of salivary glands, Ann. Surg. Oncol., 16, 751, 10.1245/s10434-008-0259-6 · doi:10.1245/s10434-008-0259-6
- Siemeister, 1998, An antagonistic vascular endothelial growth factor (VEGF) variant inhibits VEGF-stimulated receptor autophosphorylation and proliferation of human endothelial cells, Proc. Natl. Acad. Sci. USA., 95, 4625, 10.1073/pnas.95.8.4625 · DOI
- Suri, 1996, Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis, Cell., 87, 1171, 10.1016/S0092-8674(00)81813-9 · DOI · Paper page
- Sweeney, 2002, Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production, Clin. Cancer Res., 8, 2714
- Thomas, 2007, A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer, Ann. Oncol., 18, 782, 10.1093/annonc/mdl469 · DOI
- von Tell, 2006, Pericytes and vascular stability, Exp. Cell Res., 312, 623, 10.1016/j.yexcr.2005.10.019 · DOI · Paper page
- Weis, 1989, Differential effects of nerve, muscle, and fat tissue on regenerating nerve fibers in vivo, Muscle Nerve., 12, 723, 10.1002/mus.880120905 · DOI
- Weis, 1995, Nerve conduction changes and fine structural alterations of extra- and intrafusal muscle and nerve fibers in streptozotocin diabetic rats, Muscle Nerve., 18, 175, 10.1002/mus.880180205 · DOI
- Wong, 1997, Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues, Circ. Res., 81, 567, 10.1161/01.RES.81.4.567 · DOI · Paper page
- Wood, 2000, PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration, Cancer Res., 60, 2178
Cited by
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
Vasudev, N. S., & Reynolds, A. R. (2014) · Angiogenesis · doi:10.1007/s10456-014-9420-y · Cited by 738
Dudley, A. C. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006536 · Cited by 424
Donnem, T., Hu, J., Ferguson, M., Adighibe, O., Snell, C., Harris, A. L., Gatter, K. C., & Pezzella, F. (2013) · Cancer Medicine · doi:10.1002/cam4.105 · Cited by 275
Controlling escape from angiogenesis inhibitors
Sennino, B., & McDonald, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3366 · Cited by 264
Contribution of Tumor Endothelial Cells in Cancer Progression
Hida, K., Maishi, N., Annan, D., & Hida, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051272 · Cited by 259
Metadata
- Authors
- Helfrich, I., Scheffrahn, I., Bartling, S., Weis, J., von Felbert, V., Middleton, M., Kato, M., Ergün, S., Augustin, H. G., & Schadendorf, D.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2010-03-01
- Volume
- 207
- Issue
- 3
- Pages
- 491-503
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W3025821417
- Cited by
- 170
- References
- 8
- FWCI
- 7.92
- Type
- journal article
- Language
- en
- Update notices
- correction (2013-04-08)
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. https://app.cochat.ai/papers/10.1084/jem.20091846
- The paper
- Helfrich, I., Scheffrahn, I., Bartling, S., Weis, J., von Felbert, V., Middleton, M., Kato, M., Ergün, S., Augustin, H. G., & Schadendorf, D. (2010). Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20091846
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.